Danielle Miller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Danielle Miller has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Mark Butler
Northwell, New Hyde Park, NY 11042-1069, USA
12 shared publications - Alexandra Perrin
Northwell, 2000 Marcus Ave, Suite 300, New Hyde Park, NY, 11042, United States, 646-995-8958
9 shared publications - Karina W. Davidson
Northwell, New Hyde Park, NY 11042-1069, USA
9 shared publications - Ying Kuen Cheung
Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY
9 shared publications - Ashley M. Goodwin
Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health , Manhasset, New York
8 shared publications - Ciaran P. Friel
Northwell, 2000 Marcus Ave, Suite 300, New Hyde Park, NY, 11042-1069, United States, 1 6467667181
7 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by Oxford University Press (OUP) in JAMIA Open
- Vol. 9  (6)
A framework for the aggregation and visualization of personalized N-of-1 trial data: the Personalized N-of-1 Data Wizard
Objectives: Personalized or N-of-1 cross-over controlled trials evaluate the effectiveness of an intervention within a single patient. Though data from personalized N-of-1 trials are used to inform individual treatment decisions, personalized trial data can also be aggregated to provide insights about larger populations and improve quality of population treatment decisions. Our goal is to develop a publicly available phenotyping Wizard to conduct analyses using pooled data from multiple series of personalized N-of-1 trials. Materials and methods: The current Wizard integrates data from 2 series of personalized, N-of-1 trials of yoga vs massage for improving chronic lower back pain (N = 57) and active vs sham light therapy for improving fatigue (N = 60). This online Wizard aggregates text-message ecological momentary assessment data, Fitbit wearable activity tracker data, and validated survey instruments. Results: The Wizard allows for the public and research audiences to access de-identified data from 117 personalized N-of-1 trials with up to 14 weeks of data for each trial. Users of the Wizard can view raw data, create plots of study measures over time, and use previously established analytic methods for N-of-1 trials to examine pooled and sub-group treatment effects. Discussion and Conclusion: Data from a personalized N-of-1 trial is seldom analyzed after it has been used to inform an individual patient’s treatment. This Wizard provides an interactive method for visualizing and analyzing aggregated standardized data taken from personalized trials. This platform encourages the use of personalized trial data to explore group phenotypes for treatment response.
- 6 November 2026
- Published by Oxford University Press (OUP) in JAMIA Open
- Vol. 9  (6)
Open AccessA framework for the aggregation and visualization of personalized N-of-1 trial data: the Personalized N-of-1 Data Wizard
Objectives: Personalized or N-of-1 cross-over controlled trials evaluate the effectiveness of an intervention within a single patient. Though data from personalized N-of-1 trials are used to inform individual treatment decisions, personalized trial data can also be aggregated to provide insights about larger populations and improve quality of population treatment decisions. Our goal is to develop a publicly available phenotyping Wizard to conduct analyses using pooled data from multiple series of personalized N-of-1 trials. Materials and methods: The current Wizard integrates data from 2 series of personalized, N-of-1 trials of yoga vs massage for improving chronic lower back pain (N = 57) and active vs sham light therapy for improving fatigue (N = 60). This online Wizard aggregates text-message ecological momentary assessment data, Fitbit wearable activity tracker data, and validated survey instruments. Results: The Wizard allows for the public and research audiences to access de-identified data from 117 personalized N-of-1 trials with up to 14 weeks of data for each trial. Users of the Wizard can view raw data, create plots of study measures over time, and use previously established analytic methods for N-of-1 trials to examine pooled and sub-group treatment effects. Discussion and Conclusion: Data from a personalized N-of-1 trial is seldom analyzed after it has been used to inform an individual patient’s treatment. This Wizard provides an interactive method for visualizing and analyzing aggregated standardized data taken from personalized trials. This platform encourages the use of personalized trial data to explore group phenotypes for treatment response.
- Open Access
- 9 June 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15  (1) , e82857
Multicomponent Behavior Change Technique Intervention for Caregivers of People With Alzheimer Disease and Related Dementias: Protocol for a Single-Arm, Personalized Behavioral Trial to Disrupt Sedentary Time
Background: Sedentary behavior is associated with negative health outcomes. High levels of sedentary behavior are common among Alzheimer disease and related dementias (ADRD) caregivers already at risk of other adverse health effects, yet few interventions target sedentary behavior within this population. There is a need for trials intended to reduce time spent sedentary, which may be achievable by increasing the frequency of disruptions to sedentary time. Remotely delivered behavior change techniques (BCTs) may be effective for disrupting sedentary behavior in this population through short bursts of walking, although it is unclear how BCTs promote this behavior and potentially act via the hypothesized mechanism of behavioral automaticity. Objective: The goal of the trial is to examine whether a significant proportion of ADRD caregivers (≥50%) receiving an SMS text message–delivered BCT intervention form a habit to engage in hourly walking 4 times per day, with the broader objective of disrupting sedentary time in this population. Methods: This trial is a 12-week, decentralized, single-arm, National Institutes of Health Stage II behavioral trial. The trial will deliver a personalized, multicomponent BCT intervention to disrupt time spent sedentary by encouraging forming a habit of hourly walking among caregivers of persons with ADRD via the key mechanism of behavior change behavioral automaticity. The intervention includes 4 daily SMS text message–delivered BCT components previously used in interventions to disrupt sedentary behavior—Goal setting, Action planning, Prompts/cues, and Self-monitoring. Formation of an hourly walking habit is the primary outcome and will be defined as walking an additional 250 steps or more per hour for the same 4 consecutive hours as set up in a personalized walking plan on 7 consecutive days. Secondary outcomes include evaluating associations between habit formation and behavioral automaticity, and between longitudinal behavioral automaticity and habitual hourly walking over time. Additionally, heterogeneity of treatment effects will be evaluated. Exploratory analyses will examine potential moderating variables that may influence the intervention effect. The trial uses digital enrollment strategies, SMS text message intervention delivery, passive data collection via Fitbit (Google) devices, and online survey assessments to collect data remotely. Results: This study was funded by the National Institute on Aging in June 2024. Recruitment and data collection began in March 2025. As of August 2025, 40% (n=40) of the planned sample has been enrolled. Data collection is expected to be complete by June 2026. Data analysis and publication of results are expected by Fall and Winter 2026, respectively. Conclusions: Results will have the potential to advance knowledge about the effectiveness of BCTs to form a habit of hourly walking and may provide opportunities for future public health impact to promote physical activity in caregivers of those living with ADRD.
- 9 June 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15  (1) , e82857
Open AccessMulticomponent Behavior Change Technique Intervention for Caregivers of People With Alzheimer Disease and Related Dementias: Protocol for a Single-Arm, Personalized Behavioral Trial to Disrupt Sedentary Time
Background: Sedentary behavior is associated with negative health outcomes. High levels of sedentary behavior are common among Alzheimer disease and related dementias (ADRD) caregivers already at risk of other adverse health effects, yet few interventions target sedentary behavior within this population. There is a need for trials intended to reduce time spent sedentary, which may be achievable by increasing the frequency of disruptions to sedentary time. Remotely delivered behavior change techniques (BCTs) may be effective for disrupting sedentary behavior in this population through short bursts of walking, although it is unclear how BCTs promote this behavior and potentially act via the hypothesized mechanism of behavioral automaticity. Objective: The goal of the trial is to examine whether a significant proportion of ADRD caregivers (≥50%) receiving an SMS text message–delivered BCT intervention form a habit to engage in hourly walking 4 times per day, with the broader objective of disrupting sedentary time in this population. Methods: This trial is a 12-week, decentralized, single-arm, National Institutes of Health Stage II behavioral trial. The trial will deliver a personalized, multicomponent BCT intervention to disrupt time spent sedentary by encouraging forming a habit of hourly walking among caregivers of persons with ADRD via the key mechanism of behavior change behavioral automaticity. The intervention includes 4 daily SMS text message–delivered BCT components previously used in interventions to disrupt sedentary behavior—Goal setting, Action planning, Prompts/cues, and Self-monitoring. Formation of an hourly walking habit is the primary outcome and will be defined as walking an additional 250 steps or more per hour for the same 4 consecutive hours as set up in a personalized walking plan on 7 consecutive days. Secondary outcomes include evaluating associations between habit formation and behavioral automaticity, and between longitudinal behavioral automaticity and habitual hourly walking over time. Additionally, heterogeneity of treatment effects will be evaluated. Exploratory analyses will examine potential moderating variables that may influence the intervention effect. The trial uses digital enrollment strategies, SMS text message intervention delivery, passive data collection via Fitbit (Google) devices, and online survey assessments to collect data remotely. Results: This study was funded by the National Institute on Aging in June 2024. Recruitment and data collection began in March 2025. As of August 2025, 40% (n=40) of the planned sample has been enrolled. Data collection is expected to be complete by June 2026. Data analysis and publication of results are expected by Fall and Winter 2026, respectively. Conclusions: Results will have the potential to advance knowledge about the effectiveness of BCTs to form a habit of hourly walking and may provide opportunities for future public health impact to promote physical activity in caregivers of those living with ADRD.
- Open Access
- 11 May 2026
- Published by Open Exploration Publishing in Exploration of Medicine
- Vol. 7, 1001402
Associations between self-reported adherence to antihypertensive medications and potential mechanisms of behavior change in a general outpatient sample
Aim: Adherence to antihypertensive medication is essential for positive outcomes among patients diagnosed with hypertension. Yet, up to 72% of individuals prescribed antihypertensives do not take medication as prescribed. Understanding mechanisms of behavior change (MoBCs) for antihypertensive adherence provides essential insight for how to change adherence behavior. This study examined the association between 4 potential MoBCs and self-reported antihypertensive adherence. Methods: This exploratory, cross-sectional study recruited 101 patients prescribed antihypertensive medications to complete self-report questionnaires on adherence and potential mechanisms of nonadherence. Antihypertensive adherence was assessed using the Hill-Bone Compliance to High Blood Pressure Therapy Scale (HB-HBP). The 4 putative MoBCs for nonadherence included self-efficacy, self-regulation, behavioral automaticity, and hypertension knowledge. Associations between self-reported antihypertensive adherence and MoBCs were examined using independent samples t-tests and multivariate median regression with covariate adjustment for participant characteristics. Results: The sample had a mean age of 61.7 years (SD = 13.1 years), was 59.4% female (n = 60), 66.3% White (n = 67), and 7.9% Hispanic (n = 8). Low adherence was reported by 16.8% of the study sample. Participants who reported low adherence to antihypertensive medications had lower scores on the self-efficacy questionnaire (p < 0.001) and hypertension knowledge (p = 0.045). Self-efficacy and hypertension knowledge remained significantly associated with self-reported adherence in multivariate regression with covariate adjustment. Conclusions: The current study supports the hypothesis that self-efficacy for adherence and additionally hypertension knowledge are the MoBCs most strongly associated with self-reported adherence behavior. Behavioral interventions to improve medication adherence should consider focusing on self-efficacy and hypertension knowledge as potentially important target MoBCs. The authors recommend that future research should consider tailored intervention approaches that target specific mechanisms of adherence and specific self-reported reasons for nonadherence.
- 11 May 2026
- Published by Open Exploration Publishing in Exploration of Medicine
- Vol. 7, 1001402
Open AccessAssociations between self-reported adherence to antihypertensive medications and potential mechanisms of behavior change in a general outpatient sample
Aim: Adherence to antihypertensive medication is essential for positive outcomes among patients diagnosed with hypertension. Yet, up to 72% of individuals prescribed antihypertensives do not take medication as prescribed. Understanding mechanisms of behavior change (MoBCs) for antihypertensive adherence provides essential insight for how to change adherence behavior. This study examined the association between 4 potential MoBCs and self-reported antihypertensive adherence. Methods: This exploratory, cross-sectional study recruited 101 patients prescribed antihypertensive medications to complete self-report questionnaires on adherence and potential mechanisms of nonadherence. Antihypertensive adherence was assessed using the Hill-Bone Compliance to High Blood Pressure Therapy Scale (HB-HBP). The 4 putative MoBCs for nonadherence included self-efficacy, self-regulation, behavioral automaticity, and hypertension knowledge. Associations between self-reported antihypertensive adherence and MoBCs were examined using independent samples t-tests and multivariate median regression with covariate adjustment for participant characteristics. Results: The sample had a mean age of 61.7 years (SD = 13.1 years), was 59.4% female (n = 60), 66.3% White (n = 67), and 7.9% Hispanic (n = 8). Low adherence was reported by 16.8% of the study sample. Participants who reported low adherence to antihypertensive medications had lower scores on the self-efficacy questionnaire (p < 0.001) and hypertension knowledge (p = 0.045). Self-efficacy and hypertension knowledge remained significantly associated with self-reported adherence in multivariate regression with covariate adjustment. Conclusions: The current study supports the hypothesis that self-efficacy for adherence and additionally hypertension knowledge are the MoBCs most strongly associated with self-reported adherence behavior. Behavioral interventions to improve medication adherence should consider focusing on self-efficacy and hypertension knowledge as potentially important target MoBCs. The authors recommend that future research should consider tailored intervention approaches that target specific mechanisms of adherence and specific self-reported reasons for nonadherence.
- Open Access
- 31 January 2026
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 162, 108248
Protocol for a single-arm, multi-component behavior change technique (BCT) intervention to develop a walking habit among caregivers for persons with Alzheimer disease and related dementias (ADRD)
- 31 January 2026
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 162, 108248
Open AccessProtocol for a single-arm, multi-component behavior change technique (BCT) intervention to develop a walking habit among caregivers for persons with Alzheimer disease and related dementias (ADRD)
- Open Access
- 4 January 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16  (1) , 23
Randomized Personalized Trial for Stress Management Compared to Standard of Care
Background/Objectives: Psychological stress is a common problem but hard to universally treat. Personalized (N-of-1) trials assess a participant’s response to multiple specific interventions. Though personalized (N-of-1) trials have been used in select interventions, no prior research has examined whether N-of-1 designs provide superior stress reduction relative to standard of care. Methods: Participants were randomized to personalized N-of-1 (N = 106) or standard-of-care (N = 106) arms for three stress-management interventions (mindfulness meditation; yoga; brisk walking). All participants completed ecological momentary assessments (EMA) of stress three times daily for 18 weeks (2-week baseline, 12-week intervention, 2-week assessment, and 2-week follow-up). After the intervention, participants in the N-of-1 arms received a personalized report identifying which intervention worked best for them. All participants chose one intervention to manage their stress during follow-up. The primary outcome was change in perceived stress between baseline and follow-up. Results: Participants in the personalized (N-of-1) arms did not report significantly reduced EMA stress levels relative to standard-of-care (p = 0.496), though the effect was stronger among N-of-1 participants who chose the stress-management intervention recommended by their report [B(SE) = −0.67(0.34); p = 0.049]. Conclusions: Results show the potential of personalized (N-of-1) trials to provide individuals with information unique to them to help identify interventions for stress management. However, many participants in the personalized trial arms did not choose the intervention recommended by their trial. Additional research is required to refine how personalized (N-of-1) trials are conducted and how trial results are reported to participants to ensure the maximal benefit of these trial designs.
- 4 January 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16  (1) , 23
Open AccessRandomized Personalized Trial for Stress Management Compared to Standard of Care
Background/Objectives: Psychological stress is a common problem but hard to universally treat. Personalized (N-of-1) trials assess a participant’s response to multiple specific interventions. Though personalized (N-of-1) trials have been used in select interventions, no prior research has examined whether N-of-1 designs provide superior stress reduction relative to standard of care. Methods: Participants were randomized to personalized N-of-1 (N = 106) or standard-of-care (N = 106) arms for three stress-management interventions (mindfulness meditation; yoga; brisk walking). All participants completed ecological momentary assessments (EMA) of stress three times daily for 18 weeks (2-week baseline, 12-week intervention, 2-week assessment, and 2-week follow-up). After the intervention, participants in the N-of-1 arms received a personalized report identifying which intervention worked best for them. All participants chose one intervention to manage their stress during follow-up. The primary outcome was change in perceived stress between baseline and follow-up. Results: Participants in the personalized (N-of-1) arms did not report significantly reduced EMA stress levels relative to standard-of-care (p = 0.496), though the effect was stronger among N-of-1 participants who chose the stress-management intervention recommended by their report [B(SE) = −0.67(0.34); p = 0.049]. Conclusions: Results show the potential of personalized (N-of-1) trials to provide individuals with information unique to them to help identify interventions for stress management. However, many participants in the personalized trial arms did not choose the intervention recommended by their trial. Additional research is required to refine how personalized (N-of-1) trials are conducted and how trial results are reported to participants to ensure the maximal benefit of these trial designs.
- Open Access
- 26 September 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9, e58192
A Series of Personalized Melatonin Supplement Interventions for Poor Sleep: Feasibility Randomized Crossover Trial for Personalized N-of-1 Treatment
Background: Poor sleep (defined by short sleep duration or poor quality) is a common condition with potential serious health consequences. Exogenous melatonin supplements have been found to effectively improve poor sleep but have also been shown to have heterogeneity of treatment effects (HTEs) between individuals. Personalized N-of-1 trials, in which each participant is the unit of analysis, are ideal for identifying whether a treatment with high HTE is beneficial for each individual patient. Objective: This study aimed to identify the feasibility, acceptability, and effectiveness of a series of personalized N-of-1 trials of melatonin for poor sleep. Methods: This study consisted of 60 digital, personalized N-of-1 crossover trials comparing the effects of 3.0 mg and 0.5 mg of melatonin versus placebo for poor sleep with randomization to 1 of 2 orders. The trial comprised a 2-week baseline period and a 12-week intervention period. The primary outcomes were usability of the personalized trial system (measured using the System Usability Scale [SUS]) and participant satisfaction with the trial. Effectiveness outcomes included sleep duration (measured using a Fitbit activity tracker [Google]) and sleep quality (measured using the consensus sleep diary). Results: Participants rated the usability of the personalized trial as acceptable (average SUS score 76.3, SD 17.1), and 96% (55/57) of those who completed satisfaction surveys stated that they would recommend the trial to others. Importantly, indices of HTE were low for 3.0 mg and 0.5 mg doses of melatonin, indicating that the effect of these treatments on sleep duration and sleep quality did not substantially vary between participants and that averaged treatment responses are appropriate. Averaged participant sleep duration did not significantly differ between the 3.0 mg (P=.70) and 0.5 mg (P=.90) melatonin intervention periods and the baseline period. In addition, regression models did not show differences between different levels of melatonin and placebo periods for sleep duration or quality. Conclusions: Participant ratings of the usability of and satisfaction with this series of personalized N-of-1 trials of melatonin for sleep suggest these trials are both feasible and acceptable. However, our results show that melatonin supplements did not significantly improve sleep duration or sleep quality. Furthermore, the treatment effects’ lack of heterogeneity among participants suggests that future use of N-of-1 trials of melatonin for poor sleep is not needed.
- 26 September 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9, e58192
Open AccessA Series of Personalized Melatonin Supplement Interventions for Poor Sleep: Feasibility Randomized Crossover Trial for Personalized N-of-1 Treatment
Background: Poor sleep (defined by short sleep duration or poor quality) is a common condition with potential serious health consequences. Exogenous melatonin supplements have been found to effectively improve poor sleep but have also been shown to have heterogeneity of treatment effects (HTEs) between individuals. Personalized N-of-1 trials, in which each participant is the unit of analysis, are ideal for identifying whether a treatment with high HTE is beneficial for each individual patient. Objective: This study aimed to identify the feasibility, acceptability, and effectiveness of a series of personalized N-of-1 trials of melatonin for poor sleep. Methods: This study consisted of 60 digital, personalized N-of-1 crossover trials comparing the effects of 3.0 mg and 0.5 mg of melatonin versus placebo for poor sleep with randomization to 1 of 2 orders. The trial comprised a 2-week baseline period and a 12-week intervention period. The primary outcomes were usability of the personalized trial system (measured using the System Usability Scale [SUS]) and participant satisfaction with the trial. Effectiveness outcomes included sleep duration (measured using a Fitbit activity tracker [Google]) and sleep quality (measured using the consensus sleep diary). Results: Participants rated the usability of the personalized trial as acceptable (average SUS score 76.3, SD 17.1), and 96% (55/57) of those who completed satisfaction surveys stated that they would recommend the trial to others. Importantly, indices of HTE were low for 3.0 mg and 0.5 mg doses of melatonin, indicating that the effect of these treatments on sleep duration and sleep quality did not substantially vary between participants and that averaged treatment responses are appropriate. Averaged participant sleep duration did not significantly differ between the 3.0 mg (P=.70) and 0.5 mg (P=.90) melatonin intervention periods and the baseline period. In addition, regression models did not show differences between different levels of melatonin and placebo periods for sleep duration or quality. Conclusions: Participant ratings of the usability of and satisfaction with this series of personalized N-of-1 trials of melatonin for sleep suggest these trials are both feasible and acceptable. However, our results show that melatonin supplements did not significantly improve sleep duration or sleep quality. Furthermore, the treatment effects’ lack of heterogeneity among participants suggests that future use of N-of-1 trials of melatonin for poor sleep is not needed.
- Open Access
- 16 April 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 27, e54629
Digital, Personalized Clinical Trials Among Older Adults, Lessons Learned From the COVID-19 Pandemic, and Directions for the Future: Aggregated Feasibility Data From Three Trials Among Older Adults
Background: The COVID-19 pandemic was extremely disruptive to clinical practice and research. Given older adults’ increased likelihood of chronic health concerns, limited resources, and greater risk for adverse outcomes of COVID-19, access to research participation during this time was critical, particularly to interventions that may impact health conditions or behaviors. Fortunately, the implementation of personalized, digital research trials during the pandemic allowed for research and intervention delivery for older adults to continue remotely, resulting in feasibility findings that can benefit researchers, practitioners, and the broader older adult population. Objective: This study discusses 3 digital, remote, and personalized intervention trials implemented during the pandemic to increase physical activity (2 trials) or to reduce back pain (1 trial). Methods: We identified measures used for all 3 trials including Fitbit activity monitor use and self-reported participant satisfaction. Participant levels of Fitbit activity monitor use and satisfaction ratings of the digital trials were compared between younger (younger than 55 years) and older adults (older than 55 years). Differences between these cohorts were analyzed using chi-square tests for categorical outcomes and 2-tailed independent-sample t tests for continuous outcomes. Results: Across the 3 trials, the majority of participants reported high satisfaction with the usability of the trials’ digital systems including SMS text message interventions and surveys (≥62% satisfied) and the use of wearable devices such as Fitbits (≥81% satisfied). In addition, the use of the Fitbit device was shown to be feasible, as older adults across all trials wore their Fitbits for the majority of the day (mean 20.3, SD 3.6 hours). Furthermore, consistent Fitbit wear was common; 100% of participants older than 55 years wore their Fitbit an average of 10 or more hours per day. These trials highlight that digital, remote intervention delivery may be successfully implemented among older adults by way of personalized trials. Across the 3 digital interventions, feasibility and acceptability were high among older adults, and comparable to younger adults. Conclusions: Given the success of the current trials amid pandemic restrictions, we argue that these trials serve as a useful framework to aid in designing personalized, digital, remote interventions in other areas of clinical care among older adults and in planning for future disruptions including new pandemics.
- 16 April 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 27, e54629
Open AccessDigital, Personalized Clinical Trials Among Older Adults, Lessons Learned From the COVID-19 Pandemic, and Directions for the Future: Aggregated Feasibility Data From Three Trials Among Older Adults
Background: The COVID-19 pandemic was extremely disruptive to clinical practice and research. Given older adults’ increased likelihood of chronic health concerns, limited resources, and greater risk for adverse outcomes of COVID-19, access to research participation during this time was critical, particularly to interventions that may impact health conditions or behaviors. Fortunately, the implementation of personalized, digital research trials during the pandemic allowed for research and intervention delivery for older adults to continue remotely, resulting in feasibility findings that can benefit researchers, practitioners, and the broader older adult population. Objective: This study discusses 3 digital, remote, and personalized intervention trials implemented during the pandemic to increase physical activity (2 trials) or to reduce back pain (1 trial). Methods: We identified measures used for all 3 trials including Fitbit activity monitor use and self-reported participant satisfaction. Participant levels of Fitbit activity monitor use and satisfaction ratings of the digital trials were compared between younger (younger than 55 years) and older adults (older than 55 years). Differences between these cohorts were analyzed using chi-square tests for categorical outcomes and 2-tailed independent-sample t tests for continuous outcomes. Results: Across the 3 trials, the majority of participants reported high satisfaction with the usability of the trials’ digital systems including SMS text message interventions and surveys (≥62% satisfied) and the use of wearable devices such as Fitbits (≥81% satisfied). In addition, the use of the Fitbit device was shown to be feasible, as older adults across all trials wore their Fitbits for the majority of the day (mean 20.3, SD 3.6 hours). Furthermore, consistent Fitbit wear was common; 100% of participants older than 55 years wore their Fitbit an average of 10 or more hours per day. These trials highlight that digital, remote intervention delivery may be successfully implemented among older adults by way of personalized trials. Across the 3 digital interventions, feasibility and acceptability were high among older adults, and comparable to younger adults. Conclusions: Given the success of the current trials amid pandemic restrictions, we argue that these trials serve as a useful framework to aid in designing personalized, digital, remote interventions in other areas of clinical care among older adults and in planning for future disruptions including new pandemics.
- Open Access
- 10 September 2024
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 41, 101364
Protocol for a personalized (N-of-1) trial for testing the effects of a mind–body intervention on sleep duration in middle-aged women working in health care
- 10 September 2024
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 41, 101364
Open AccessProtocol for a personalized (N-of-1) trial for testing the effects of a mind–body intervention on sleep duration in middle-aged women working in health care
- Open Access
- 11 March 2024
- Published by JMIR Publications Inc. in JMIR Preprints
A Series of Personalized Melatonin Supplement Interventions for Poor Sleep: Feasibility Randomized Crossover Trial for Personalized N-of-1 Treatment (Preprint)
BACKGROUND Poor sleep (defined by short sleep duration or poor quality) is a common condition with potential serious health consequences. Exogeneous melatonin supplements have been found to effectively improve poor sleep but have also been shown to have heterogeneity of treatment effects (HTEs) between individuals. Personalized N-of-1 trials, in which each participant is the unit of analysis, are ideal for identifying whether a treatment with high HTE is beneficial for each individual patient. OBJECTIVE This study aimed to identify the feasibility, acceptability, and effectiveness of a series of personalized N-of-1 trials of melatonin for poor sleep. METHODS This study consisted of 60 digital, personalized N-of-1 crossover trials comparing the effects of 3.0mg and 0.5mg of melatonin versus placebo for poor sleep with randomization to 1 of 2 orders. The trial was comprised of a 2-week baseline period and a 12-week intervention period. The primary outcomes were usability of the personalized trial system (measured using the System Usability Scale [SUS]) and participant satisfaction with the trial. Effectiveness outcomes included sleep duration (measured using a Fitbit activity tracker) and sleep quality (measured using the consensus sleep diary [CSD]). RESULTS Participants rated the usability of the personalized trial as acceptable (average SUS score=76.3 [standard deviation (SD)=17.1]), and 96% (55/57) of those who completed satisfaction surveys stated that they would recommend the trial to others. Importantly, indices of HTE were low for 3.0mg and 0.5mg doses of melatonin, indicating that the effect of these treatments on sleep duration and sleep quality did not substantially vary between participants and that averaged treatment responses are appropriate. Averaged participant sleep duration did not significantly differ between the 3.0mg (P=0.7) and 0.5mg (P=0.9) melatonin intervention periods and the baseline period. Additionally, regression models did not show differences between different levels of melatonin and placebo periods for sleep duration or quality. CONCLUSIONS Participant ratings of the usability of and satisfaction with this series of personalized N-of-1 trials of melatonin for sleep suggest these trials are both feasible and acceptable. However, our results show that melatonin supplements did not significantly improve sleep duration or sleep quality. Further, the treatment effects’ lack of heterogeneity between participants suggests that future use of N-of-1 trials of melatonin for poor sleep is not needed.
- 11 March 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessA Series of Personalized Melatonin Supplement Interventions for Poor Sleep: Feasibility Randomized Crossover Trial for Personalized N-of-1 Treatment (Preprint)
BACKGROUND Poor sleep (defined by short sleep duration or poor quality) is a common condition with potential serious health consequences. Exogeneous melatonin supplements have been found to effectively improve poor sleep but have also been shown to have heterogeneity of treatment effects (HTEs) between individuals. Personalized N-of-1 trials, in which each participant is the unit of analysis, are ideal for identifying whether a treatment with high HTE is beneficial for each individual patient. OBJECTIVE This study aimed to identify the feasibility, acceptability, and effectiveness of a series of personalized N-of-1 trials of melatonin for poor sleep. METHODS This study consisted of 60 digital, personalized N-of-1 crossover trials comparing the effects of 3.0mg and 0.5mg of melatonin versus placebo for poor sleep with randomization to 1 of 2 orders. The trial was comprised of a 2-week baseline period and a 12-week intervention period. The primary outcomes were usability of the personalized trial system (measured using the System Usability Scale [SUS]) and participant satisfaction with the trial. Effectiveness outcomes included sleep duration (measured using a Fitbit activity tracker) and sleep quality (measured using the consensus sleep diary [CSD]). RESULTS Participants rated the usability of the personalized trial as acceptable (average SUS score=76.3 [standard deviation (SD)=17.1]), and 96% (55/57) of those who completed satisfaction surveys stated that they would recommend the trial to others. Importantly, indices of HTE were low for 3.0mg and 0.5mg doses of melatonin, indicating that the effect of these treatments on sleep duration and sleep quality did not substantially vary between participants and that averaged treatment responses are appropriate. Averaged participant sleep duration did not significantly differ between the 3.0mg (P=0.7) and 0.5mg (P=0.9) melatonin intervention periods and the baseline period. Additionally, regression models did not show differences between different levels of melatonin and placebo periods for sleep duration or quality. CONCLUSIONS Participant ratings of the usability of and satisfaction with this series of personalized N-of-1 trials of melatonin for sleep suggest these trials are both feasible and acceptable. However, our results show that melatonin supplements did not significantly improve sleep duration or sleep quality. Further, the treatment effects’ lack of heterogeneity between participants suggests that future use of N-of-1 trials of melatonin for poor sleep is not needed.
- Open Access
- 16 November 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Digital, Personalized Clinical Trials Among Older Adults, Lessons Learned From the COVID-19 Pandemic, and Directions for the Future: Aggregated Feasibility Data From Three Trials Among Older Adults (Preprint)
BACKGROUND The COVID-19 pandemic was extremely disruptive to clinical practice and research. Given older adults’ increased likelihood of chronic health concerns, limited resources, and greater risk for adverse outcomes of COVID-19, access to research participation during this time was critical, particularly to interventions that may impact health conditions or behaviors. Fortunately, the implementation of personalized, digital research trials during the pandemic allowed for research and intervention delivery for older adults to continue remotely, resulting in feasibility findings that can benefit researchers, practitioners, and the broader older adult population. OBJECTIVE This study discusses 3 digital, remote, and personalized intervention trials implemented during the pandemic to increase physical activity (2 trials) or to reduce back pain (1 trial). METHODS We identified measures used for all 3 trials including Fitbit activity monitor use and self-reported participant satisfaction. Participant levels of Fitbit activity monitor use and satisfaction ratings of the digital trials were compared between younger (younger than 55 years) and older adults (older than 55 years). Differences between these cohorts were analyzed using chi-square tests for categorical outcomes and 2-tailed independent-sample t tests for continuous outcomes. RESULTS Across the 3 trials, the majority of participants reported high satisfaction with the usability of the trials’ digital systems including SMS text message interventions and surveys (≥62% satisfied) and the use of wearable devices such as Fitbits (≥81% satisfied). In addition, the use of the Fitbit device was shown to be feasible, as older adults across all trials wore their Fitbits for the majority of the day (mean 20.3, SD 3.6 hours). Furthermore, consistent Fitbit wear was common; 100% of participants older than 55 years wore their Fitbit an average of 10 or more hours per day. These trials highlight that digital, remote intervention delivery may be successfully implemented among older adults by way of personalized trials. Across the 3 digital interventions, feasibility and acceptability were high among older adults, and comparable to younger adults. CONCLUSIONS Given the success of the current trials amid pandemic restrictions, we argue that these trials serve as a useful framework to aid in designing personalized, digital, remote interventions in other areas of clinical care among older adults and in planning for future disruptions including new pandemics. CLINICALTRIAL
- 16 November 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessDigital, Personalized Clinical Trials Among Older Adults, Lessons Learned From the COVID-19 Pandemic, and Directions for the Future: Aggregated Feasibility Data From Three Trials Among Older Adults (Preprint)
BACKGROUND The COVID-19 pandemic was extremely disruptive to clinical practice and research. Given older adults’ increased likelihood of chronic health concerns, limited resources, and greater risk for adverse outcomes of COVID-19, access to research participation during this time was critical, particularly to interventions that may impact health conditions or behaviors. Fortunately, the implementation of personalized, digital research trials during the pandemic allowed for research and intervention delivery for older adults to continue remotely, resulting in feasibility findings that can benefit researchers, practitioners, and the broader older adult population. OBJECTIVE This study discusses 3 digital, remote, and personalized intervention trials implemented during the pandemic to increase physical activity (2 trials) or to reduce back pain (1 trial). METHODS We identified measures used for all 3 trials including Fitbit activity monitor use and self-reported participant satisfaction. Participant levels of Fitbit activity monitor use and satisfaction ratings of the digital trials were compared between younger (younger than 55 years) and older adults (older than 55 years). Differences between these cohorts were analyzed using chi-square tests for categorical outcomes and 2-tailed independent-sample t tests for continuous outcomes. RESULTS Across the 3 trials, the majority of participants reported high satisfaction with the usability of the trials’ digital systems including SMS text message interventions and surveys (≥62% satisfied) and the use of wearable devices such as Fitbits (≥81% satisfied). In addition, the use of the Fitbit device was shown to be feasible, as older adults across all trials wore their Fitbits for the majority of the day (mean 20.3, SD 3.6 hours). Furthermore, consistent Fitbit wear was common; 100% of participants older than 55 years wore their Fitbit an average of 10 or more hours per day. These trials highlight that digital, remote intervention delivery may be successfully implemented among older adults by way of personalized trials. Across the 3 digital interventions, feasibility and acceptability were high among older adults, and comparable to younger adults. CONCLUSIONS Given the success of the current trials amid pandemic restrictions, we argue that these trials serve as a useful framework to aid in designing personalized, digital, remote interventions in other areas of clinical care among older adults and in planning for future disruptions including new pandemics. CLINICALTRIAL